Literature DB >> 18836464

Management of Wilms tumor: current standard of care.

Geoffrey Sonn1, Linda M D Shortliffe.   

Abstract

Wilms tumor is the most common renal malignancy in children. In the 1930s, overall survival for children with Wilms tumor was approximately 30%. Use of multidisciplinary therapy, guided by results from multi-institutional, randomized trials, has substantially improved overall survival to about 90%. Management of Wilms tumor differs substantially between Europe and the US. In Europe, the International Society of Pediatric Oncology protocols call for management of patients with presumptive Wilms tumor with neoadjuvant chemotherapy followed by nephrectomy and further chemotherapy. In the US, protocols developed by the National Wilms Tumor Study Group advise primary nephrectomy followed by a chemotherapy regimen tailored to the pathologic tumor stage. Despite these disparate strategies, overall survival is similar in patients managed according to European and US protocols. Patients with Wilms tumor now have excellent survival. Therefore, current goals aim to reduce the morbidity associated with therapy. Important complications of treatment for Wilms tumor include cardiomyopathy, renal failure, and increased risk of a secondary malignancy. Currently, the role of laparoscopic surgery in management of Wilms tumor remains extremely limited.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836464     DOI: 10.1038/ncpuro1218

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  21 in total

Review 1.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.

Authors:  Yajun Yi; Dina Polosukhina; Harold D Love; Austin Hembd; Michael Pickup; Harold L Moses; Harold N Lovvorn; Roy Zent; Peter E Clark
Journal:  J Urol       Date:  2015-04-29       Impact factor: 7.450

3.  β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Authors:  Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

4.  MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm's tumor via Wnt/β-catenin signaling pathway.

Authors:  Xiu-Ling Liang; Yu-Long Wang; Pei-Rong Wang
Journal:  Mol Cell Biochem       Date:  2021-02-18       Impact factor: 3.396

5.  Prediction of histopathological local staging by radiological findings and differential diagnosis overview in children with nephroblastoma.

Authors:  Radu Ninel Bălănescu; Laura Bălănescu; Tudor Stejărel Strîmbu; Ancuţa Mihaela Cardoneanu; Andreea Alecsandra Moga
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

Review 6.  Wilms' tumor.

Authors:  Andrew M Davidoff
Journal:  Curr Opin Pediatr       Date:  2009-06       Impact factor: 2.856

7.  Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro.

Authors:  Jenny Wegert; Sabrina Bausenwein; Susanne Kneitz; Sabine Roth; Norbert Graf; Eva Geissinger; Manfred Gessler
Journal:  Mol Cancer       Date:  2011-11-08       Impact factor: 27.401

8.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

9.  Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Authors:  Kylie M Drake; E Cristy Ruteshouser; Rachael Natrajan; Phyllis Harbor; Jenny Wegert; Manfred Gessler; Kathy Pritchard-Jones; Paul Grundy; Jeffrey Dome; Vicki Huff; Chris Jones; Micheala A Aldred
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

10.  HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients.

Authors:  Lourdes Hontecillas-Prieto; Daniel J García-Domínguez; Rosa García-Mejías; Gema L Ramírez-Villar; Carmen Sáez; Enrique de Álava
Journal:  Oncotarget       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.